| 来源类型 | Discussion paper
|
| 规范类型 | 论文
|
| 来源ID | DP12420
|
| DP12420 Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets |
| Margaret Kyle
|
| 发表日期 | 2017-11-02
|
| 出版年 | 2017
|
| 语种 | 英语
|
| 摘要 | This paper focuses on the relationship between therapeutic value and different measures of market rewards (the number of patents, price, market share, and total revenues) of a new treatment. Using an assessment of therapeutic value provided by the French Haute Authorité de Santé (HAS), I find a weak relationship between most measures of rewards and this assessment of therapeutic value, suggesting that the returns to developing a “me-too” product are not very different from developing treatments with greater therapeutic effects. One interpretation is that the HAS score is a poor assessment of therapeutic value, in which case the use of similar health technology assessments by governments and other payers should be re-examined. Alternatively, if the HAS score is informative, the results suggest countries are spending too much on less innovative products, and that a re-balancing of innovation incentives may be worth considering if therapeutic value is highly related to social welfare. |
| 主题 | Industrial Organization
|
| URL | https://cepr.org/publications/dp12420
|
| 来源智库 | Centre for Economic Policy Research (United Kingdom)
|
| 资源类型 | 智库出版物
|
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/541229
|
推荐引用方式
GB/T 7714 |
Margaret Kyle. DP12420 Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets. 2017.
|
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
